secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVVITY, INC. (RVTY)
CIK:        0000031791
Form:       8-K
Filed at:   2021-09-21T23:59:59+00:00
Accession:  0001193125-21-277478
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 2.01, 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PerkinElmer closes $5.25B BioLegend acquisition; issues ~14.1M shares as stock consideration
--------------------------------------------------------------------------------

- Aggregate purchase price ~$5.25B; paid 59.5% cash and 40.5% stock valued at $156.3561/share.
- Cash funded by $2.28B notes offering, $500M term loan draw, ~$300M revolver draw, and cash on hand.
- Transaction closed on September 17, 2021; previously announced on July 25, 2021.
- Issued 14,066,771 shares of common stock in a private placement to BioLegend stockholders.
- Financial statements and pro forma information to be filed by amendment within 71 days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/31791/000119312521277478/0001193125-21-277478-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/31791/000119312521277478/d233653d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-277478

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer